Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
Flora Pirozzi, Remo Poto, Luisa Aran, et al.
Current Oncology Reports (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 53

Showing 26-50 of 53 citing articles:

Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta‐analysis
M. Malaty, A. Amarasekera, Cindy Li, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 12
Closed Access | Times Cited: 11
Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias?
Annamaria Mascolo, Liberata Sportiello, Concetta Rafaniello, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114912-114912
Open Access | Times Cited: 6
Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
Sridha Ganesh, Peng Zhong, Xiaoyang Zhou
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 10
Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs
Yihan Zhou, Shan Ding
Cancers (2023) Vol. 15, Iss. 23, pp. 5622-5622
Open Access | Times Cited: 5
Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 625-625
Open Access | Times Cited: 4
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Yao Liang, Osamu Maeda, Yuichi Ando
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 4, pp. 365-375
Open Access | Times Cited: 1
Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review
Jinxiong Xia, Yingmei Wen, Mengxia Xiao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Exosomes from human bone marrow MSCs alleviate PD-1/PD-L1 inhibitor-induced myocardial injury in melanoma mice by regulating macrophage polarization and pyroptosis
Bingqian Zhou, Qin Qin, Fang Yue, et al.
Life Sciences (2024) Vol. 358, pp. 123108-123108
Closed Access | Times Cited: 1
Phenotypic insights into genetic risk factors for immune-related adverse events in cancer immunotherapy
Haochuan Ma, Dili Song, Haibo Zhang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 74, Iss. 1
Open Access | Times Cited: 1
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Jennifer M. Kwan, Miles Shen, Narjes Akhlaghi, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0314555-e0314555
Open Access | Times Cited: 1
Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
Hongxiang Ji, Zhijian Wen, Bin Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Myocarditis and pericarditis following mRNA COVID-19 vaccination in younger patients: is there a shared thread?
Raffaella Mormile
Expert Review of Cardiovascular Therapy (2022) Vol. 20, Iss. 2, pp. 87-90
Open Access | Times Cited: 6
PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
Guili Huang, Songqin Liu, Jie Dong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
Late-Onset Hemorrhagic Pericardial Effusion and Cardiac Tamponade Associated With Immune Checkpoint Inhibitors: Case Report and Literature Review
Aleksan Khachatryan, Joel Manuel Alejandro, Robert D. Chow, et al.
Cureus (2023)
Open Access | Times Cited: 2
The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System
C Green, Jessica Chacon, Brandon Godinich, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5707-5707
Open Access | Times Cited: 2
Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology
David Kersting, Stephan Settelmeier, Ilektra-Antonia Mavroeidi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3802-3802
Open Access | Times Cited: 4
Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
Fengze Sun, Dawei Wang, Aina Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 3
The role of tumor types in immune-related adverse events
Qian Xu, Jing Hu, Yan Wang, et al.
Clinical & Translational Oncology (2024)
Open Access
Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity
静宜 任
Advances in Clinical Medicine (2024) Vol. 14, Iss. 03, pp. 284-290
Closed Access
Extracellular Vesicles from Human Bone Marrow Mscs Alleviate Pd-1/L1 Inhibitor-Induced Cardiac Injury in Melanoma Mice by Regulating Macrophage Polarization and Pyroptosis
Bingqian Zhou, Qin Qin, Fang Yue, et al.
(2024)
Closed Access
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma
Yu Jen Jan, Cho‐Han Chiang, Soravis Osataphan, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009769-e009769
Open Access
The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma
Yunmeng Yi, Xiaoqi Liu, Hanyu Gao, et al.
Biochemical Genetics (2023) Vol. 61, Iss. 6, pp. 2401-2424
Closed Access | Times Cited: 1
Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms
Takahiro Osawa, Takashige Abe, Hiroshi Kikuchi, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0265230-e0265230
Open Access | Times Cited: 2
Editorial: Assessment and management of adverse drug reactions in oncology
Ping-Feng Tsai, Kevin Sheng‐Kai
Frontiers in Allergy (2023) Vol. 4
Open Access
Risk factors and clinical outcomes of immune checkpoint inhibitor-related pneumonitis in patients with advanced non-small cell lung cancer：A single center experience
Ning Wang, Renzhe Xiao, Yulin Liu
Research Square (Research Square) (2023)
Open Access

Scroll to top